SCHEMBL4024987

SCHEMBL4024987

CC(C)(C)C(C[C@]1(c2cccc(Cl)c2)C[C@@H]1CCOCc1ccccc1)NC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.36
CYP3A4 P08684 4/20 0.34
CYP2C9 P11712 3/20 0.34
CYP2C19 P33261 2/20 0.34
PPARA Q07869 1/20 0.34
CYP2D6 P10635 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
LMNA P02545 4/20 0.33
MAPT P10636 3/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
ALOX12 P18054 1/20 0.33
PTPN7 P35236 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
HTT P42858 1/20 0.33
MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6173844 0.83 PPARA (0.38) CYP3A4CYP2C9CYP2C19PPARALMNA
SCHEMBL4024998 0.78 GRM5 (0.37) GRM5SLC6A4OPRK1
SCHEMBL6184557 0.78 GRM5 (0.37) GRM5SLC6A4OPRK1
SCHEMBL4024991 0.78 L3MBTL1 (0.41) GRM5PPARASLC6A4OPRK1
SCHEMBL4019223 0.77 HTR2C (0.41) GRM5CYP3A4SLC6A4SLC6A3
SCHEMBL6172455 0.73 SLC6A2 (0.36) CYP2D6SLC6A4SLC6A3OPRK1
SCHEMBL6182513 0.68 SLC6A2 (0.32) SLC6A4LMNAHTTTSHR
SCHEMBL4024334 0.68 GRM5 (0.37) GRM5
SCHEMBL6172595 0.68 EPHX2 (0.38) CYP3A4CYP2C9CYP2C19PPARALMNA
SCHEMBL6172548 0.68 EPHX2 (0.38) CYP3A4CYP2C9CYP2C19PPARALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569579-B2 for inhibition of HIV replication and treatment of acquired immune deficiency syndrome SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
EP-1569934-B1 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2008-01-23 EP disclosed
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists SMITHKLINE BEECHAM CORPORATION 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists CCR5, CCR1, CCL5 GRM5 494/4885CYP3A4 790/4885CYP2C9 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.